Back

Kelun-Biotech HER2 ADC posts 11.1-month median PFS versus 4.4 months for T-DM1

Verifying
  • Kelun-Biotech published phase III results for trastuzumab botidotin against T-DM1 in advanced HER2-positive breast cancer.
  • Median PFS was 11.1 months versus 4.4 months, with a hazard ratio of 0.39.
  • NMPA approved trastuzumab botidotin for adults after one or more prior anti-HER2 therapies.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.